Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Semaglutide D Formulations (DV3396 vs PDS290 Pen-Injectors)
NCT04152915Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement and Maximum observed semaglutide concentration. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04152915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152915.